Amitriptyline and Paroxetine Treatment of Major Depression
NCT ID: NCT01049347
Last Updated: 2024-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
127 participants
INTERVENTIONAL
1997-10-31
2000-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mineralocorticoid Receptor in the Treatment of Severe Depression
NCT00295347
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
NCT00018759
Strategic Use of New Generation Antidepressants for Depression
NCT01109693
Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome
NCT01518634
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder
NCT00955955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
amitriptyline
amitriptyline
150 mg oral, daily, single evening dose, 35 days
paroxetine
paroxetine
40 mg oral, single dose, morning, 35 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amitriptyline
150 mg oral, daily, single evening dose, 35 days
paroxetine
40 mg oral, single dose, morning, 35 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* depression according DSM-IV
Exclusion Criteria
* substance dependency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Institute of Mental Health, Mannheim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Institute of Mental Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Deuschle, MD
Role: PRINCIPAL_INVESTIGATOR
Central Institute of Mental Health, Mannheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Institute of Mental Health
Mannheim, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schilling C, Gilles M, Blum WF, Daseking E, Colla M, Weber-Hamann B, Lederbogen F, Krumm B, Heuser I, Wudy SA, Kopf D, Deuschle M. Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? J Clin Psychopharmacol. 2013 Feb;33(1):99-103. doi: 10.1097/JCP.0b013e31827cb179.
Paslakis G, Kopf D, Westphal S, Gilles M, Lederbogen F, Hamann B, Heuser I, Deuschle M. Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. J Psychopharmacol. 2011 Oct;25(10):1344-6. doi: 10.1177/0269881110382469. Epub 2010 Oct 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DFG De 660/1-1
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
AmiPar
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.